RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone
- 1 January 1999
- journal article
- clinical trial
- Published by Elsevier BV in Kidney International
- Vol. 55 (1), 299-307
- https://doi.org/10.1046/j.1523-1755.1999.00240.x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failureAmerican Journal of Kidney Diseases, 1997
- Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitroJournal of Bone and Mineral Research, 1996
- Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D.JCI Insight, 1995
- Calcemic response to parathyroid hormone in renal failure: Role of phosphorus and its effect on calcitriolKidney International, 1991
- Calcium Carbonate as a Phosphate Binder in Patients with Chronic Renal Failure Undergoing DialysisNew England Journal of Medicine, 1986
- Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysisThe Journal of Pediatrics, 1986
- Role of aluminum hydroxide in raising serum aluminum levels in children undergoing continuous ambulatory peritoneal dialysisThe Journal of Pediatrics, 1984
- The Use of Deferoxamine in the Management of Aluminum Accumulation in Bone in Patients with Renal FailureNew England Journal of Medicine, 1984
- The Prevalence of Bone Aluminum Deposition in Renal Osteodystrophy and Its Relation to the Response to Calcitriol TherapyNew England Journal of Medicine, 1982
- Osteomalacia in Chronic Renal Failure: a Syndrome Previously Reported Only with Maintenance DialysisAmerican Journal of Nephrology, 1982